In patients who have human epidermal growth factor receptor 2 - mutant (HER2 mutant) metastatic NSCLC, the use of trastuzumab deruxtecan has shown efficacy and safety in management of BM. Here, ERBB2 is linked to non-small cell lung carcinoma.